Is Xeris Pharmaceuticals Inc (XERS) overvalued? · rev $175.2M
Xeris Pharmaceuticals Inc (XERS) is a biotechnology company listed on US.
This page asks whether Xeris Pharmaceuticals Inc (XERS) looks expensive on cached numbers — not a short thesis.
Latest reported XERS revenue for 2026-06-30 was $175.2M. Net income was -$28.9M. XERS currently screens at market cap $760.7M.
XERS currently screens at market cap $760.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next XERS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the XERS stock page for the full model, not this heading.
Not investment advice.